规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
研究了单剂量氟米松(0.5 mg/100 kg bw)对小牛胰岛素敏感性的影响。在氟米松治疗前后进行了高胰岛素、正常血糖钳夹试验。治疗后 24 小时,胰岛素依赖性葡萄糖利用率降低了 74%(P < 0.005)。治疗后 72 小时未发生显著变化。[1]
|
---|---|
体内研究 (In Vivo) |
给奶牛注射 500 ml 50% 葡萄糖溶液。静脉注射,肌肉注射 40 mg 地塞米松(第 1 组);肌肉注射 40 mg 地塞米松(第 2 组);5 mg 氟米松(第 3 组);或静脉注射 500 ml 50% 葡萄糖溶液,静脉注射,肌肉注射 5 mg 氟米松(第 4 组)。治疗成功定义为在同一哺乳期内单次治疗后痊愈且无复发。子宫疾病(胎盘滞留或子宫炎)、产次、治疗前血浆葡萄糖、血清 β-羟基丁酸和尿液乙酰乙酸浓度被评估为影响痊愈的可能混杂因素。[2]
|
药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
Minimal if applied topically Metabolism / Metabolites Primarily hepatic |
参考文献 |
Zentralbl Veterinarmed A.1998 Sep;45(6-7):441-3;J Am Vet Med Assoc.1996 May 15;208(10):1702-4.
|
其他信息 |
Flumethasone is a fluorinated steroid, a glucocorticoid, an 11beta-hydroxy steroid, a 17alpha-hydroxy steroid, a 21-hydroxy steroid, a 20-oxo steroid, a 3-oxo-Delta(1),Delta(4)-steroid, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It has a role as an anti-inflammatory drug. It derives from a hydride of a pregnane.
Flumethasone is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching. An anti-inflammatory glucocorticoid used in veterinary practice. See also: Flumethasone Pivalate (is active moiety of) ... View More ... Drug Indication For the treatment of contact dermatitis, atopic dermatitis, exczema, psoriasis, diaper rash and other skin conditions Mechanism of Action Flumethasone is a glucocorticoid receptor agonist. This complex binds to the nucleus causing a variety of genetic activation and repressions. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Flumethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin. Pharmacodynamics Flumethasone pivalate is a moderately potent difluorinated corticosteroid ester with anti-inflammatory, antipruritic and vasoconstrictive properties. As it is a privalate salt, its anti-inflammatory action is concentrated at the site of application. This local effect on diseased areas results in a prompt decrease in inflammation, exudation and itching. |
分子式 |
C22H28F2O5
|
|
---|---|---|
分子量 |
410.45
|
|
精确质量 |
410.19
|
|
CAS号 |
2135-17-3
|
|
相关CAS号 |
|
|
PubChem CID |
16490
|
|
外观&性状 |
White to off-white solid powder
|
|
密度 |
1.4±0.1 g/cm3
|
|
沸点 |
569.8±50.0 °C at 760 mmHg
|
|
熔点 |
237-240ºC
|
|
闪点 |
298.4±30.1 °C
|
|
蒸汽压 |
0.0±3.6 mmHg at 25°C
|
|
折射率 |
1.579
|
|
LogP |
1.61
|
|
tPSA |
94.83
|
|
氢键供体(HBD)数目 |
3
|
|
氢键受体(HBA)数目 |
7
|
|
可旋转键数目(RBC) |
2
|
|
重原子数目 |
29
|
|
分子复杂度/Complexity |
839
|
|
定义原子立体中心数目 |
9
|
|
SMILES |
C[C@@H]1C[C@H]2[C@@H]3C[C@@H](C4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C)F
|
|
InChi Key |
WXURHACBFYSXBI-GQKYHHCASA-N
|
|
InChi Code |
InChI=1S/C22H28F2O5/c1-11-6-13-14-8-16(23)15-7-12(26)4-5-19(15,2)21(14,24)17(27)9-20(13,3)22(11,29)18(28)10-25/h4-5,7,11,13-14,16-17,25,27,29H,6,8-10H2,1-3H3/t11-,13+,14+,16+,17+,19+,20+,21+,22+/m1/s1
|
|
化学名 |
(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
|
|||
---|---|---|---|---|
溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (6.09 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (6.09 mM) (饱和度未知) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL澄清DMSO储备液加入900 μL 20% SBE-β-CD生理盐水溶液中,混匀。 *20% SBE-β-CD 生理盐水溶液的制备(4°C,1 周):将 2 g SBE-β-CD 溶解于 10 mL 生理盐水中,得到澄清溶液。 View More
配方 3 中的溶解度: ≥ 2.5 mg/mL (6.09 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4364 mL | 12.1818 mL | 24.3635 mL | |
5 mM | 0.4873 mL | 2.4364 mL | 4.8727 mL | |
10 mM | 0.2436 mL | 1.2182 mL | 2.4364 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。